Atrophy of the lateral geniculate nucleus in human glaucoma detected by magnetic resonance imaging
- 1Ophthalmology & Vision Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada
- 2Laboratory Medicine & Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Canada
- 3Glaucoma and Nerve Protection Unit, St Michael’s Hospital, University of Toronto, Toronto, Canada
- 4Keenan Research Center at the Li Ka Shing Knowledge Institute of St Michael’s Hospital, University of Toronto, Toronto, Canada
- 5Division of Neuroradiology, Department of Diagnostic Imaging, St Michael’s Hospital, University of Toronto, Toronto, Canada
- 6Ophthalmic Pathology Laboratory, University of Toronto, Toronto, Canada
- Dr N Gupta, St Michael’s Hospital, 30 Bond Street, Suite 8-072, Cardinal Carter Wing, Toronto, ON M5B 1W8, Canada;
- Accepted 13 July 2008
- Published Online First 12 August 2008
Aim: To determine in vivo whether the lateral geniculate nucleus (LGN) undergoes atrophy in patients with glaucoma and vision loss compared with normal subjects.
Methods: Following institutional St Michael’s Hospital Research Ethics Board approval, a prospective and masked neuroimaging study was conducted on glaucoma patients with visual-field defects affecting both eyes (n = 10) and age-matched controls (n = 8). Following informed consent, all subjects underwent 1.5-Tesla MRI. Coronal proton density magnetic resonance images of both LGNs were obtained, and LGN height measurements were measured by consensus by three neuroradiologists masked to the diagnosis. Glaucoma and control groups were compared using the t test.
Results: Both LGNs were identified and visualised by 1.5-Tesla MRI for every subject. Compared with controls, the mean LGN heights in glaucoma were decreased in right (4.09 (0.89) mm vs 4.74 (0.54) mm, p>0.05) and left LGNs (3.98 (0.57) mm vs 4.83 (0.95) mm; p = 0.033). The combined right and left LGN height in glaucoma was significantly decreased compared with controls (8.07 (1.06) mm vs 9.56 (0.86) mm; p = 0.005).
Conclusion: In vivo MRI evidence of LGN degeneration in human glaucoma is consistent with ex vivo primate and human neuropathological studies. LGN atrophy may be a relevant biomarker of visual system injury and/or progression in some glaucoma patients.
Competing interests: None.
Funding: This work was supported in part by the Canadian Glaucoma Clinical Research Council (NG, YY) and by the Nicky and Thor Eaton Fund (NG). The authors would like to thank J Lo for her excellent clinical study coordination.
Ethics approval: Ethics approval was provided by St Michael’s Hospital Research Ethics Board.
Patient consent: Obtained.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.